ArticleMedical care2009
Longitudinal racial/ethnic disparities in antimanic medication use in bipolar-I disorder.
Article in Medical care, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Clinician descriptions of communication strategies to improve treatment engagement by racial/ethnic minorities in mental health services: A systematic review.Patient education and counseling · 2016Pooled it
- Disruptions in Care for Medicare Beneficiaries With Severe Mental Illness During the COVID-19 Pandemic.JAMA network open · 2022Article
- Implementing parity for mental health and substance use treatment in Medicaid.Health services research · 2020Article
- Disparities in Treatment and Service Utilization Among Hispanics and Non-Hispanic Whites with Bipolar Disorder.Journal of racial and ethnic health disparities · 2017Article
- The Effects of the Transition From Medicaid to Medicare on Health Care Use for Adults With Mental Illness.Medical care · 2016Article
- The development of the DSM-5 Cultural Formulation Interview-Fidelity Instrument (CFI-FI): a pilot study.Journal of health care for the poor and underserved · 2014Article
- Effects of Medicare Part D on guideline-concordant pharmacotherapy for bipolar I disorder among dual beneficiaries.Psychiatric services (Washington, D.C.) · 2014Article
- Racial-ethnic differences in incident olanzapine use after an FDA advisory for patients with schizophrenia.Psychiatric services (Washington, D.C.) · 2013Article
- Changes in antipsychotic use among patients with severe mental illness after a Food and Drug Administration advisory.Pharmacoepidemiology and drug safety · 2012Article
- Characteristics associated with inpatient versus outpatient status in older adults with bipolar disorder.Journal of geriatric psychiatry and neurology · 2012Article
- The effect of ethnicity on prescribing practice and treatment outcome in inpatients suffering from schizophrenia in Greece.BMC psychiatry · 2011Article
- Changes in guideline-recommended medication possession after implementing Kendra's law in New York.Psychiatric services (Washington, D.C.) · 2010Article
- The rise and fall of gabapentin for bipolar disorder: a case study on off-label pharmaceutical diffusion.Medical care · 2010Article
- Disparities in outpatient visits for mental health and/or substance use disorders during the COVID surge and partial reopening in Massachusetts.General hospital psychiatryObservational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectiveTo examine racial/ethnic longitudinal disparities in antimanic medication use among adults with bipolar-I disorder.
methodsObservational study using administrative data from Florida's Medicaid program, July 1997 to June 2005, for enrollees diagnosed with bipolar-I disorder (N = 13,497 persons; 126,413 person-quarters). We examined the likelihood of receiving one of the following during a given quarter: (1) any antimanic agent (antipsychotic or mood stabilizer) or none, and (2) mood stabilizers, antipsychotic monotherapy, or neither. Binary and multinomial logistic regression models predicted the association between race/ethnicity and prescription fills, adjusting for clinical and demographic characteristics. Cohort indicators for year that the enrollee met study criteria were included to account for cohort effects.
resultsAveraging over all cohorts and quarters, compared with whites, blacks had lower odds of filling any antimanic and mood stabilizer prescriptions specifically (40%-49% and 47%-63%, respectively), but similar odds of filling prescriptions for antipsychotic monotherapy. After Bonferroni adjustment, compared with whites, there were no statistically significant disparities for Hispanics in filling prescriptions for any, or specific antimanic medications.
conclusionsRates of antimanic medication use were low regardless of race/ethnicity. However, we found disparities in antimanic medication use for blacks compared with whites and these disparities persisted over time. We found no Hispanic-white disparities. Quality improvement efforts should focus on all individuals with bipolar disorder, but particular attention should be paid to understanding disparities in medication use for blacks.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.